Skip directly to content

By Jeremiah Johnson

Since 2014, several states, cities, and counties have announced plans to End the Epidemic (EtE), with many more preparing to announce their own initiatives in 2018. In New York, early successes have emerged in the most recent surveillance data (see: “New York State EtE Campaign Update: Successes & Challenges,” and several other jurisdictions are seeing the benefits of EtE plan implementation. However, a number of common challenges have become apparent across different jurisdictions.

By Tim Horn

Do your little bit of good where you are; it’s those little bits of good put together that overwhelm the world.
                                                                      — Desmond Mpilo Tutu

Incremental change—activism that successfully defends or advances critical research or policy—can sometimes feel inconsequential, particularly when it is hard won, resource intensive, and intangible. But in the context of public health strategies with ambitious targets and formidable stakeholder engagement, it is an undeniable facet of progress. In this issue of TAGline, we

August 23, 2018 – Treatment Action Group seeks a dynamic intern to support the hepatitis C virus program. This is an unpaid internship position and would be suitable to serve as course credit.

Treatment Action Group’s Hepatitis C Virus Project reviews the state of research on HCV monoinfection and coinfection. It advocates for better clinical trial designs, access to curative treatment for all affected communities, and it continually monitors standards of care for people with HCV monoinfection and coinfection.

Slide Decks for Updated Training Manual for Treatment Advocates: Hepatitis C Virus & Coinfection with HIV

Click this link to go to the main Updated Training Manual for Treatment Advocates: Hepatitis C Virus & Coinfection with HIV webpage, which includes the training manual's description and PDFs in English and French.

Final FY18 Appropriations Resist Trump Administration’s Anti-Science Rhetoric, Affirm the Value of Research and Programs in the Elimination of HIV, Tuberculosis and Hepatitis C; Prevention Programs Must be Further Strengthened in FY19

Treatment Action Group (TAG) lauds Congress on soundly rejecting the President’s anti-science rhetoric with a fiscal year 2018 (FY18) appropriations bill that affirms the value of research and evidence-based programs to catalyze the elimination of HIV, tuberculosis (TB), and hepatitis C virus (HCV) domestically and internationally.

 “We urge Congress to build


Download this release as a PDF

New York Community Groups Call on City, State, Federal Actors to Increase Funding for Tuberculosis
Advocates alarmed that budget cuts led to first rise in TB cases in New York City in over 25 years

Erica Lessem, Treatment Action Group, 617-827-2461,
Amanda Lugg, African Services Committee, 212-222-3882, x2148,
Mika De Roo, Housing Works, 347-585-6051,

NEW YORK, March 22, 2018 – African Services Committee, FPWA, Hispanic Federation, Hispanic Health

As we discussed in Part I of this webinar series, pregnant women have frequently been excluded from or de-prioritized in clinical research initiatives due to a multitude of factors, such as the complex physiology of pregnant women, the risk studies may pose to the fetus, and the classification of pregnant women as a vulnerable population, among others. This neglect has left pregnant women and their providers to make decisions without adequate information or guidance regarding the safety and efficacy of necessary treatments.

Part II of this webinar series was held on Wednesday, March 14th,

For Immediate Release

Annette Gaudino, 718-208-7531,

ALBANY, NY, MARCH 16 – Responding to unprecedented advocacy by community leaders, people living with hepatitis C, and communities impacted by the epidemic, Governor Cuomo today announced New York State’s commitment to eliminate hepatitis C as a public health threat. The Governor’s announcement makes New York State the first jurisdiction to declare the intention to eliminate hepatitis C, the deadliest infectious disease in the U.S.

Is Shorter Better? Understanding the Shorter Regimen For Treating Drug-Resistant Tuberculosis

Multidrug-resistant TB (MDR-TB) is a growing problem around the world, and is difficult to treat. In 2016, the World Health Organization (WHO) recommended a shorter regimen for treating MDR-TB. Now, data from a randomized controlled trial are available. This new brief from TAG and DR-TB STAT explains what the shorter regimen is, who can receive it, and its advantages and disadvantages. 

If you want to learn even more, check out the webinar we held on the phase III trial of the shorter regimen and on the phase III trial of

Issue Brief: Suboptimal Immune Recovery on Antiretroviral Therapy


For many HIV-positive people—particularly those who initiate treatment soon after infection—combination antiretroviral therapy (ART) is associated with robust improvements in CD4+ T cell counts, enhanced immune function, and a life expectancy comparable to that of similar HIV-negative individuals.

But a subset of people on ART experience limited or no recovery of CD4+ T cell counts despite achieving and maintaining undetectable HIV viral loads, and these individuals have an elevated risk of illness and death compared with counterparts who obtain greater CD4+ T cell gains.